米托克桑2HCl对宫癌复制和维护蛋白的巧妙活性:一种多目标的方法
Mohammed Ageeli Hakami1, Ali Hazazi2, Mishal Olayan Alsulami3
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Al-Quwayiyah, Riyadh, Saudi Arabia.
Journal of biomolecular structure & dynamics
|March 22, 2024
概括
宫癌是全球主要的健康问题,需要新的治疗方法. 这项研究确定了Mitoxantrone 2HCl作为对关键宫癌蛋白质的有前途的多目标抑制剂,需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 计算生物学 计算生物学
- 药物发现 药物发现 药物发现
背景情况:
- 宫癌是全球女性的主要死亡原因,主要是由高风险的人类乳头瘤病毒 (HPV) 类型16和18驱动的.
- 开发多向抑制剂对于提高治疗疗效和克服宫癌治疗中的耐药性至关重要.
研究的目的:
- 确定FDA批准的药物作为潜在的多位抑制剂,对抗宫癌复制和维护蛋白.
- 用计算方法评估候选药物的结合亲和力和分子相互作用.
主要方法:
- 美国食品和药物管理局 (FDA) 批准的药物的多目标分子对接对抗Xenopus kinesin-like protein-2 (3KND),细胞分裂周期蛋白-20 (4N14),MCM2-基因组复合物 (4UUZ) 和MCM6 (2KLQ).
- 使用HTVS,SP和XP算法,然后使用MM/GBSA计算来估计约束能量.
- 分析了分子相互作用指纹,药理动力学,DFT,并进行了100 ns的分子动力学模拟以评估稳定性.
主要成果:
- 米托克桑2HCl与对接和MM/GBSA得分表现出显著的结合亲和力,分别在8.492~5.189Kcal/mol和58.16~39.07Kcal/mol之间.
- 关键的相互作用涉及疏水性和极性氨基酸,包括ALA,THR,SER,ASN,LEU和ILE.
- 分子动力学模拟表明稳定的复合物形成,具有有前途的药理动力学和DFT结果.
结论:
- 米托克桑2HCl显示出作为对关键宫癌蛋白质的多目标抑制剂的潜力.
- 进一步的实验验证是必要的,以确认其治疗疗效和人类使用的安全性.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Electron Transport Chain: Complex I and II
13.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.2K


